MAT: Recovery in a Bottle: For Best Results….

What do the drugs methadone, buprenorphine and naltrexone contribute to recovery? That question has various answers, depending on who is asking and who is answering. With Opiate Use Disorder triggering an overdose epidemic, the search for solutions has become desperate. Saving lives has become a priority, acutely and from a prevention viewpoint. The directive is to help individuals avoid tragedy and find recovery.
Many find hope in utilizing Medication Assisted Treatment (MAT) with the medications listed above. Many others believe that recovery is based in the individual’s effort, and that medication hinders that effort. Still, others are unsure, and believe that any and all “tools” should be utilized.
What does history tell us? What data and outcomes exist to help us decide which path is the right one for each individual? What impact do regulators, health systems, physicians, pharmaceutical manufacturers, and the treatment community make toward effectively treating those with Opiate Use Disorder?
This workshop will review the biological basis of opiate dependency and the proposed mechanisms of MAT medications on the symptoms of opiate withdrawal and recovery. We will explore the available data produced in clinical trials of these medications. Investigate the “evidence-base”, best practice guidelines, and economic market influences on treatment application. We will also, consider new models of treatment delivery based on medication delivery, treatment team coordination and individualized, patient-centered care that acknowledges challenges, limitations and benefits one patient at a time.

Date: 
Wednesday, March 28, 2018 - 9:00am to 4:00pm
PCB Hours Approved: 
6 hrs
Presenter: 
Michael Palladini, RPh, MBA
Go to top